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Abstract
Introduction: Clinically evaluating genotypic interpretation systems is essential to provide optimal guidance in designing
potent individualized HIV-regimens. This study aimed at investigating the ability of the latest Rega algorithm to predict
virological response on a short and longer period.
Materials & Methods: 9231 treatment changes episodes were extracted from an integrated patient database. The
virological response after 8, 24 and 48 weeks was dichotomized to success and failure. Success was defined as a viral load
below 50 copies/ml or alternatively, a 2 log decrease from the baseline viral load at 8 weeks. The predictive ability of Rega
version 8 was analysed in comparison with that of previous evaluated version Rega 5 and two other algorithms (ANRS
v2011.05 and Stanford HIVdb v6.0.11). A logistic model based on the genotypic susceptibility score was used to predict
virological response, and additionally, confounding factors were added to the model. Performance of the models was
compared using the area under the ROC curve (AUC) and a Wilcoxon signed-rank test.
Results: Per unit increase of the GSS reported by Rega 8, the odds on having a successful therapy response on week 8
increased significantly by 81% (OR= 1.81, CI = [1.76–1.86]), on week 24 by 73% (OR = 1.73, CI = [1.69–1.78]) and on week 48
by 85% (OR= 1.85, CI = [1.80–1.91]). No significant differences in AUC were found between the performance of Rega 8 and
Rega 5, ANRS v2011.05 and Stanford HIVdb v6.0.11, however Rega 8 had the highest sensitivity: 76.9%, 76.5% and 77.2% on
8, 24 and 48 weeks respectively. Inclusion of additional factors increased the performance significantly.
Conclusion: Rega 8 is a significant predictor for virological response with a better sensitivity than previously, and with rules
for recently approved drugs. Additional variables should be taken into account to ensure an effective regimen.
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Introduction
Since the advent of Highly Active Anti Retroviral Therapy
(HAART), morbidity and mortality related with HIV/AIDS have
considerably decreased in the Western world [1]. Clinicians can
now compose several efficient combination regimens using 25
approved drugs [2]. Nevertheless, in many patients, not all options
can be used, due to intolerance or side effects for certain drugs and
because of the presence of antiviral drug (cross-)resistance [3].
Extended cross-resistance has been decreasing over calendar year
and drug developers have been encouraged to focus their research
on new potent drugs with a better tolerability, ease of use and less
toxicity [4]. Nevertheless, resistance is and will continue to be an
important issue in the management of HIV. Correct interpretation
of the mutational patterns is however not straightforward, and
unfortunately there is no consensus on this matter yet. Several
genotypic interpretation systems have proven to significantly
predict virologic response in retrospective analyses [5–7] and are
therefore mentioned in treatment and resistance guidelines [8].
However, it remains a challenge to keep those interpretation
systems up-to-date and improve their usefulness for clinicians
treating HIV-infected patients [9]. New knowledge on resistance
related mutations is accumulating and new drugs are still being
implemented in clinical practice. Thus, guidelines stress the fact
that regular updating and proper clinical evaluation of interpre-
tation algorithms is needed [8].
The Rega algorithm was initiated in January 2000 and the
current version Rega 8 dates from June 2009. Previous versions
have been retrospectively evaluated with focus on short term viral
response in HIV-1 patients (3 months) [6,10–14]. Here the results
of the clinical evaluation of Rega 8 for prediction of virologic
response on short (8 weeks), mid-long (24 weeks) and long (48
weeks) term based on a large clinical database are presented,
including a comparison with the HIVdb v6.0.11 and ANRS
2011.05 algorithms and a previous version of the Rega algorithm
(Rega 5).
Materials and Methods
An integrated database was set up using data originating from
different countries: Belgium, Germany, Israel, Italy, Luxembourg,
Portugal, Spain and Sweden, in collaboration with the EuResist
consortium. This data didn’t serve as base for the construction of
the rules-based interpretation systems discussed in this paper.
RegaDB was used to manage and analyse the data in the
integrated database [15], from which treatment change episodes
(TCEs) were extracted. A TCE was defined as the start of a first
line or follow-up therapy with the corresponding baseline variables
and follow-up viral load measurements. A baseline PR-RT
genotype and viral load measurement was required between 90
days before and one week after the start of the new therapy and at
Table 1. Dataset characteristics.
Number of TCEs 9231
Age, median (IQR), in years 40 11
Male, no. (%) 6378 71
Ethnicity, no. (%)
Caucasian 1500 16
Asian 684 7
African 679 7
Unknown 6368 69
Risk group, no. (%)
Heterosexual contact 3620 35
Men who have sex with men 2427 26
Injection drug use 1888 20
Transfusion 109 1
Vertical 124 1
Other 92 1
Unkown 1331 14
Subtype B, no. (%) 6649 72
Therapy start year, median (min-max) 2004 1994–2010
Follow-up time points, no. (%)
At 8 weeks 8294 90
At 24 weeks 8566 93
At 48 weeks 7576 82
Success rate, no. (%)
At 8 weeks 4937 60
At 24 weeks 4262 50
At 48 weeks 7576 47
New drug class in treatment, no. (%)
NRTI 5769 62
NNRTI 721 8
PI 3465 38
Number of previous therapy switches,
mean (SD)
4.15 4.02
Therapy experiencea, no. (%)
NRTI 4919 53
NNRTI 2139 23
PI 3590 39
Antiviral resistanceb, no. (%)
NRTI 4127 45
NNRTI 2300 25
PI 1905 21
Number of resistance mutations, mean (SD)
NRTI 1.30 1.85
NNRTI 0.38 0.74
PI 0.42 0.97
Baseline CD4 cell count, cells/mm3,
median (IQR)
232 260
Baseline HIV-RNA load, log10 copies/ml, mean
(min-max)
5.23 0–7.54
Genotypic Susceptibility Score (GSS), median
Rega 5 3
Table 1. Cont.
Number of TCEs 9231
Rega 8 3
Stanford HIVdb v6.0.11 3
ANRS v2011.05 3
Characteristics of patients and treatment change episodes.
aAt least 1 year of experience with a drug class.
bAt least 1 resistance mutation from the IAS 2010 list.
doi:10.1371/journal.pone.0061436.t001
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least one follow-up viral load measurement. Virological outcome
of each TCE was assessed at 8, 24 and 48 weeks based on the latest
viral load measurement. At 8 weeks, we defined virological success
as the achievement of a viral load less than 50 copies/ml or a
decrease from the baseline viral load by two or more Logs. At 24
and 48 weeks, the virological success was defined as the
achievement of a viral load less than 50 copies/ml. No restrictions
on therapies were contemplated, i.e. suboptimal treatment
regimens made of less than three drugs were allowed. However
TCEs containing inhibitors against other viral proteins than
protease or reverse transcriptase were excluded because only PR-
RT sequences were available. The following compounds, all
currently approved by the Food and Drug Administration (FDA)
(http://www.fda.gov/oashi/aids/virals.html) and European Med-
icines Agency (EMEA) (http://www.emea.europa.eu) were con-
sidered: nucleotide/side reverse transcriptase inhibitors (N(t)RTIs):
zidovudine (AZT), stavudine (D4T), zalcitabine (DDC), abacavir
(ABC), lamivudine (3TC), emtricitabine (FTC), didanosine (DDI),
tenofovir (TDF); non-nucleoside reverse transcriptase inhibitors
(NNRTIs): efavirenz (EFV), nevirapine (NVP), etravirine (ETR);
protease inhibitors (PIs): amprenavir (APV), fosamprenavir (FPV),
atazanavir (ATV), indinavir (IDV), lopinavir (LPV/r), nelfinavir
(NFV), saquinavir (SQV), tipranavir (TPV), darunavir (DRV),
along with boosting ritonavir (RTV). If multiple TCEs were
available for a single patient, one was randomly selected to ensure
a single TCE per patient. Based on previous reports [10,13],
potential confounding factors were included, if data on them was
available: age, gender, risk group, baseline viral load and CD4
count, year of therapy start, introduction of a new drug class in the
regimen, number of previous therapy switches and information on
drug class experience (defined as more than 1 year on NRTIs,
NNRTIs or PIs, respectively).
The viral genotypes were subtyped using version 2 of the Rega
HIV-1 subtyping tool [16] and resistance interpretation was
performed by Rega 5 (version 5.5; December 2001) and Rega 8
(version 8.0.2; June 2009) [14], version 6.0.11 (March 2011) of the
Stanford HIVdb algorithm [17] and version 20 (May 2011) of the
ANRS algorithm [18]. These algorithms (available as supplemen-
tary material) were used to assign a resistance score to each drug in
the administered regimen. The Rega 5 algorithm and the ANRS
algorithm consider 3 levels of resistance (corresponding with scores
0, 0.5, 1). The Stanford HIVdb algorithm considers 5 levels (0,
0.25, 0.5, 0.75 and 1). In the Rega 8 algorithm, the resistance
scores are weighted based on the estimated potency and genetic
barrier of the corresponding drug or drug class. The scores of
boosted PIs are changed to 0, 0.75 and 1.5 and those for NNRTIs
(except etravirine) become 0, 0.25 and 1 for resistant, intermediate
resistant and susceptible respectively. Subsequently, the arithmetic
sum of the scores for all drugs in the regimen was calculated to
achieve the genotypic susceptibility score (GSS) of the regimen.
Rules are removed from the algorithm when a drug is no longer
used in clinical practice and new rules are implemented as soon as
drug resistance mutations are known for a newly available drug. In
order to compare Rega 5 and 8 on the same dataset, rules for an
absent drug were copied from the other algorithm. Rules for
boosted and un-boosted PIs were interchanged after correcting the
weights. Rules for FTC and 3TC and for APV and its pro-drug
FPV were interchanged. Full versions of the Rega algorithm can
be found on the website of the KU Leuven http://regaweb.med.
kuleuven.be/software/rega_algorithm/.
As the primary objective, the performance of Rega 8 was
checked by univariate and multivariate logistic regression on the
full dataset stratified for the three follow-up times and the odds
ratio (OR), 95% confidence interval (CI) and p-values are
reported. As a secondary objective, a comparison of Rega 8 with
Rega 5, ANRS and Stanford HIVdb was performed. The
individual performances were compared by means of a Receiver
Operation Characteristic (ROC) analysis and Area Under the
Figure 1. Prevalence rates (%) of antiretroviral drugs. Nucleotide/side reverse transcriptase inhibitors (N(t)RTIs): lamivudine (3TC), tenofovir
(TDF), zidovudine (AZT), emtricitabine (FTC), didanosine (DDI), abacavir (ABC), stavudine (D4T), zalcitabine (DDC); non-nucleoside reverse
transcriptase inhibitors (NNRTIs): efavirenz (EFV), nevirapine (NVP), etravirine (ETR); protease inhibitors (PIs): lopinavir (LPV/r), atazanavir (ATV),
nelfinavir (NFV), saquinavir (SQV), indinavir (IDV), fosamprenavir (FPV), darunavir (DRV), amprenavir (APV), tipranavir (TPV), along with boosting
ritonavir (RTV).
doi:10.1371/journal.pone.0061436.g001
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ROC Curve (AUC) was adopted by using 10-fold cross-validation.
AUCs were then compared by using a Wilcoxon signed-rank test
[19]. P-values were corrected for multiple testing using the
Benjamini-Hochberg procedure. Additionally, the sensitivity was
investigated for each individual algorithm using the GSS cut-off of
3 as suggested by recent guidelines [8]. Sensitivity (true positive
rate) was defined as the ratio of the number of TCEs with a GSS of
at least 3 and with virological success over the total number of
virological successes. Specificity (true negative rate) was the ratio of
the number of TCEs with a GSS less than the GSS cut-off and
with virological failure over the total number of virological failures.
Results
Descriptive Statistics
9231 TCEs were extracted from the integrated database
(Table 1). Median patient age was 40 years. 71% of patients were
men, 35% were heterosexual, 26% were men who have sex with
men and 20% were intravenous drug users. Most patients were
infected with a subtype B virus (72%). Other prevalent (w1%)
subtypes were subtype A (6%), subtype C (6%), CRF 02_AG (3%),
subtype G (2%) and subtype F (2%). The ethnicity was unknown
for most patients (69%). At baseline, the median CD4 cell count
was 232 cells/mm3 and mean HIV-RNA load (viral load) 5.23
log10 copies/ml. 90% of the TCEs had a follow-up viral load
measurement at 8 weeks, 93% at 24 and 82% at 48 weeks. The
success rate dropped from 60% at 8 weeks to 50% at 24 weeks and
to 47% at 48 weeks. The start date of the TCEs ranged from 1994
to 2010. 62% of the TCEs started for the first time with an NRTI,
8% with an NNRTI and 38% with a PI. The most prevalent drug
administrated in the TCEs was 3TC, followed by TDF, LPV/r
and AZT (Figure 1). At the start of the new regimen, experience
for more than 1 year with an NRTI occurred in 53%, with an
NNRTI in 23% and with a PI in 39% of the patients. The mean
GSS reported by the algorithms ranged from 2.40 to 2.80 with
standard deviations between 0.78 and 0.93 (Figure 2).
Performance of Rega 8
The odds ratios, 95% confidence intervals and p-values of the
logistic regression models were determined for 8, 24 and 48 weeks
response using the univariate approach (Table 2). The GSS as
reported by Rega 8 was predictive for the virological success at all
time-points. Per unit increase of the GSS, the odds on having a
successful therapy response on week 8 increased by 81%
(OR = 1.81, CI = [1.76–1.86], Pv0:001), on week 24 by 73%
(OR = 1.73, CI = [1.69–1.78], Pv0:001) and on week 48 by 85%
(OR = 1.85, CI = [1.80–1.91], Pv0:001) (Table 2). The ROC
analysis of the 10-fold cross-validation showed that the inclusion of
all available covariates significantly increased the performance of
Rega 8 on all time points (P~0:006, P~0:003 and P~0:003 for
week 8, 24 and 48 respectively). Also ANRS and HIVdb improved
Figure 2. Distribution of the regimen-specific genotypic susceptibility scores reported by different versions of the Rega algorithm,
ANRS v2011.05 and Stanford HIVdb v6.0.11.
doi:10.1371/journal.pone.0061436.g002
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significantly when adding covariates to the model (Figure 3 for 24
weeks results).
Comparison with Rega 5, ANRS and Stanford HIVdb
Algorithms
Rega 8 and Rega 5 performed equally well in predicting
virological success on all time-points as the AUC was not
statistically different: P~0:145, P~0:782 and P~0:578 for week
8, 24 and 48 respectively (Table 2). However, Rega 8 had a higher
sensitivity than Rega 5:76.9% versus 67.4%, 76.5% versus 66.6%
and 77.2% versus 67.4% on 8, 24 and 48 weeks respectively
(Table 3). Without applying weights to the rules in Rega 8, the
sensitivity decreased to 73.4%, 72.5% and 73.2% on 8, 24 and 48
weeks respectively.
The performance of Rega 8 was further compared to those of
the ANRS and Stanford HIVdb algorithms. No significant
differences in AUC were found after correcting for multiple
testing (Table 2). Both ANRS and Stanford HIVdb had a lower
sensitivity than Rega 8: respectively 74.5% and 65.8% compared
to 76.9% on 8 weeks, 74.1% and 64.1% compared to 76.5% on 24
weeks and 74.8% and 64.9% compared to 77.2% on 48 weeks.
Discussion
In this study the Rega HIV drug resistance interpretation
algorithm version 8 was retrospectively evaluated and compared
with other systems using in vivo data from 9231 patients. We
applied the algorithm to the baseline genotype and evaluated the
association with the follow-up virologic response. Virological
suppression means undetectable viral load but this threshold may
differ according to the period in which measurements were done,
with the newer viral load assays having a cut-off of 50 copies/ml.
Excluding all measurements with a cut-off different from 50
copies/ml was difficult as we had a large dataset from various
countries and laboratories that updated their assays at different
times. However, we included the start date of therapy in the
multivariate analysis to correct (partly) for those differences in
assays.
The studied algorithms, Rega, ANRS and HIVdb, were able to
significantly predict virological response of the TCEs. On average,
per unit increase of the genotypic susceptibility score of the
administrated regimen, the odds on having a successful therapy
response almost doubled. Inclusion of treatment history and
baseline patient- and viral derived characteristics enhanced the
predictive value of the model. However these factors are not
Table 2. Performance on the complete dataset.
logistic model Area under the ROC curve
approach time algorithm OR CI P Median SD Comparison*
univariate 8 weeks Rega 5 1.95 1.89–2.01 ,0.001 0.617 0.025 0.145
Rega 8 1.81 1.76–1.86 ,0.001 0.607 0.036
Rega 8 unweighted 1.90 1.85–1.96 ,0.001 0.616 0.025 0.240
ANRS 1.88 1.83–1.94 ,0.001 0.608 0.021 1.000
Stanford HIVdb 1.89 1.84–1.95 ,0.001 0.626 0.030 0.079
24 weeks Rega 5 1.80 1.75–1.86 ,0.001 0.598 0.037 0.782
Rega 8 1.73 1.69–1.78 ,0.001 0.601 0.045
Rega 8 unweighted 1.75 1.70–1.80 ,0.001 0.596 0.038 0.372
ANRS 1.74 1.69–1.79 ,0.001 0.592 0.036 0.221
Stanford HIVdb 1.69 1.64–1.73 ,0.001 0.597 0.039 0.330
48 weeks Rega 5 1.95 1.89–2.02 ,0.001 0.615 0.040 0.578
Rega 8 1.85 1.80–1.91 ,0.001 0.619 0.050
Rega 8 unweighted 1.86 1.80–1.91 ,0.001 0.608 0.039 0.145
ANRS 1.82 1.76–1.88 ,0.001 0.603 0.038 0.088
Stanford HIVdb 1.81 1.75–1.86 ,0.001 0.612 0.042 0.240
multivariate 8 weeks Rega 8 1.50 1.46–1.55 ,0.001 0.653 0.036
ANRS 1.52 1.47–1.57 ,0.001 0.652 0.037 0.913
Stanford HIVdb 1.55 1.50–1.60 ,0.001 0.655 0.038 0.555
24 weeks Rega 8 1.54 1.49–1.59 ,0.001 0.667 0.050
ANRS 1.53 1.47–1.58 ,0.001 0.663 0.050 0.162
Stanford HIVdb 1.49 1.45–1.55 ,0.001 0.663 0.049 0.145
48 weeks Rega 8 1.55 1.50–1.60 ,0.001 0.680 0.054
ANRS 1.50 1.45–1.56 ,0.001 0.675 0.056 0.145
Stanford HIVdb 1.51 1.46–1.56 ,0.001 0.676 0.054 0.145
Overview of the performance of the different algorithms using the univariate and multivariate approach and on 8, 24 and 48 weeks of therapy. The multivariate
approach includes additional variables in the model: start year of therapy, information on start of a new drug class, number of previous therapy switches, previous drug
class experience, baseline viral load, baseline CD4, gender, age, risk group. Reported are the odds ratio (OR), 95% confidence interval (CI) and P-value (P) of the logistic
model and the median and standard deviation (SD) of the 10-fold cross-validation area under the ROC curve (AUC).
*The performance of the algorithms is compared with that of Rega 8 using a Wilcoxon signed-rank test and the P-value corrected for multiple testing is reported.
doi:10.1371/journal.pone.0061436.t002
Clinical Evaluation of Rega 8
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61436
always available to the clinician nor are they automatically taken
into account by the online available interpretation systems.
The predictive value reported here can only be a combined
evaluation of the rules for those drugs that are present in all
algorithms. Rega 5 contains rules for six NRTIs (AZT, DDC,
DDI, 3TC, D4T, ABC), one NtRTI (TDF), three NNRTIs (NVP,
DLV, EFV) and six PIs (RTV, IDV, SQV, NFV, APV, LPV/r).
Rega 8 differs from Rega 5 in respect to drugs included: one
NRTI (FTC), one NNRTI (ETV), four boosted PIs (FPV(r),
ATV(r), TPVr and DRVr), two entry inhibitors (T20 and MVC)
and one integrase inhibitor (RAL) are in Rega 8 and not in Rega
5. DDC is no longer in Rega 8 (discontinued since 2006), whereas
the rules for APV are replaced by the ones for its prodrug FPV(r).
Furthermore, existing rules are updated, a score-based system for
PIs is implemented instead of logical rules and drug weighting
factors are incorportated. Finally, Rega 8 has specific rules for the
interpretation of HIV-2 drug resistance (which were not evaluated
in this study). We saw that these differences between Rega 8 and 5
didn’t influence significantly the performance of the Rega
algorithm in predicting therapy outcome. Moreover, Rega 8,
ANRS and HIVdb reached the same performance on all time-
points and using the univariate as well as the multivariate
approach. In this discussion, we explore some of the possible
reasons for this.
Our paper confirms the results of colleagues Frentz et al. [20] to
that extent that the three commonly used HIV drug resistance
interpretation systems - ANRS, Rega and HIVdb - predict
virological response to the same extent. However, our paper
evaluates more recent versions of the algorithms that are currently
being used in clinical practice. Moreover it compares the latest
Figure 3. Receiver operating Characteristic (ROC) analysis of the 24-weeks-performance of the regimen-specific genotypic
susceptibility score (GSS) according to Rega 8, ANRS v2011.05 and Stanford HIVdb v6.0.11 algorithms.
doi:10.1371/journal.pone.0061436.g003
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Rega algorithm (version 8) with the previous evaluated version 5 to
check consistency and improvement. Finally, it is for the first time
that Rega, ANRS and Stanford HIVdb algorithms were evaluated
on such an extensive dataset: 9231 TCEs from patients from
several European countries. However, we have to acknowledge
that the dataset still has its limitations. Despite the fact that the
Rega algorithm is set up to be used for all HIV subtypes, our
dataset contained 72% subtype B strains (Table 1), while the other
subtypes were underrepresented [21]. Additionally, there is a bias
present in the administered drugs: NRTIs that are commonly used
to form the backbone regimen are highly prevalent in the dataset
(e.g. 3TC was part of the regimen in almost half of the the cases),
while more recently approved drugs (e.g. ETR) are underrepre-
sented (Figure 1). Moreover, the prevalence of resistance
mutations in the dataset follows a similar distribution with NRTI
resistance being more prevalent than NNRTI or PI resistance
(Table 1). This means that studies investigating the performance of
interpretation systems specifically for recently approved drugs, less
prevalent mutations and non-B subtypes are needed [9].
Moreover, only PR or RT genotypes were available so drugs
targeting other regions had to be excluded from the dataset and
the corresponding rules were thus not evaluated in this analysis.
In agreement with other reports [13,22] we noticed that the
predictive value of the weighted rules in Rega 8 was higher
compared to the unweighted rules in Rega 5, however not
significant. This may in part be due to the fact that NNRTIs and
PIs, for which weighting factors were introduced, are less
represented in our clinical data compared to the N(t)RTIs
(Figure 1). This result corresponds with that of another study
[20] in which the introduction of weighting did not change the
GSS to a great extent.
Rega 8 had the highest sensitivity with respect to the other
studied algorithms, although its specificity was the lowest (Table 3).
This shift from specificity to sensitivity was a deliberate choice to
extend the application of the Rega algorithm. Initially its purpose
was solely to score resistance, so the previous versions of the Rega
algorithm were heavily taking into account the genetic barrier to
resistance associated with a large number of minor resistance
mutations. In the latest version of Rega this has less effect. As a
result, the focus of the algorithm shifted from predicting resistance
and consequential therapy failure to predicting virological success
in order to find an active, potent regimen. This change makes the
Rega algorithm more in alignment with the other algorithms. How
sensitivity and specificity should be balanced depends on the
number of antiviral drugs that are still active. Therefore the Rega
algorithm recommends different GSS cut-offs depending on the
patient characteristics: GSS§3 in case of therapy-naı¨ve persons
with no indications of transmitted drug resistance and in case of
therapy-experienced persons, GSS§3:5 in case of therapy-naı¨ve
persons with indications of transmitted drug resistance and
GSS§2 in case of therapy-experienced persons with limited
treatment options. A higher risk for virologic failure and resistance
development at mid-term can be expected when therapy changes
with GSS below the target GSS of 3 are installed. Using this cut-
off, Rega 8 reached a sensitivity score of 77.2% and a specificity
score of 45.8% at 48 weeks follow-up, despite the fact that
confounding factors like adherence, resistance- and treatment
history, minor variants, baseline viral load and CD4 cell count
were not taken into account. Kaplan-Meier analysis that was
performed on the time to virological failure stratified by the GSS
reported by Rega 8 showed that the Kaplan-Meier curves differed
significantly between the group with a GSS of 2 and the group
with a GSS of 3 (Pv0:001) (results not shown). This supports the
clinical relevancy of the Rega algorithm, despite the relatively small
differences that were observed in comparison with the previously
evaluated version. Regimens with 3 active drugs are required for
long-term virologic response and are therefore currently recom-
mended. However, virologic success with less potent regimens can
be observed at the short- and mid-term time-points that were
investigated in this analysis. As was in the pre-HAART era, when
bi-therapies were prescribed [23,24], some patients in our study still
succeeded therapy at 48 weeks (22.8%, 116/507) although their
GSS was 2.5 at the most. In contrast, regimens with 3 drugs lead to
48.5% (3430/7069) virological successes at 48 weeks. Three active
drugs or a target GSS of at least 3 doubles the rate of success in the
dataset. However, because genotypic interpretation systems have
been used in clinical practice since 10 years, there is a bias towards a
target GSS of 3 in the dataset (Figure 2). Therefore, not enough data
is available in our to suggest that a target GSS of 2.5 would give
similar success rates.
A previous report [14] that had as primary endpoint to evaluate
the performance of the Rega algorithm (version 5.5) described the
predictive value at 3 months. Viral load changes at that time point
reflect more the activity of the treatment on the predominant virus
population detected by baseline genotyping. However, clinicians
are more interested in the prediction of longer-term virologic
response (in our study up to 48 weeks), but then the outcome can
be more influenced by the genetic barrier to resistance. We
corrected (partly) for this bias by including information on
treatment history as a surrogate for expected HIV drug resistance
when calculating the performance of the algorithm.
In conclusion, we convincingly demonstrated that Rega 8 is
significantly predictive for virological response and that additional
variables should be taken into account to ensure an effective
regimen. There was no distinguisable trend in the performance of
the consecutive versions of the Rega algorithm, nor were there
significant differences in AUC between Rega, ANRS and HIVdb.
The clinical dataset used in this study may not have the power to
show the gain of the sometimes minor improvements to excisting
rules, of the specific rules for divergent subtypes, or of the rules for
new drugs. Nevertheless, the reported analyses need to be done
and published to give confidence to the users of the algorithms.
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Table 3. Sensitivity and Specificity.
8 weeks 24 weeks 48 weeks
Sens Spec Sens Spec Sens Spec
Rega 5 67.4 54.2 66.6 51.1 67.4 54.3
Rega 8 76.9 45.6 76.5 43.2 77.2 45.8
Rega 8
unweighted
73.4 49.1 72.5 46.1 73.2 48.6
ANRS 74.5 46.6 74.1 44.1 74.8 46.6
HIVDB 65.8 56.6 64.1 52.8 64.9 55.6
Sensitivity and specificity of the different algorithms after 8, 24 and 48 weeks of
therapy using a cut-off GSS of 3. The sensitivity was defined as the proportion
of TCEs with a GSS of 3 or more and a virological response on all those with a
virological response whereas the specificity was seen as the proportion of TCEs
with a GSS less than 3 and no virological response on all those with no
virological response.
doi:10.1371/journal.pone.0061436.t003
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